New York, United States
sales@usaonlinepharmacy.net
Sale!

Buy Watson Morphine Sulfate 80mg tablets in the USA

$370.00$3,700.00

Morphine Sulfate Extended-Release Tablets are for oral use and contain morphine sulfate, an opioid agonist.

Thumbnail Quantity PriceQuantity
Buy Watson Morphine Sulfate 80mg tablets in the USA - 1000 tablet Pack 1000 tablet Pack $3,700.00
Buy Watson Morphine Sulfate 80mg tablets in the USA - 500 tablet Pack 500 tablet Pack $3,000.00
Buy Watson Morphine Sulfate 80mg tablets in the USA - 250 tablet Pack 250 tablet Pack $2,000.00
Buy Watson Morphine Sulfate 80mg tablets in the USA - 100 tablet Pack 100 tablet Pack $700.00
Buy Watson Morphine Sulfate 80mg tablets in the USA - 50 tablet Pack 50 tablet Pack $500.00
Buy Watson Morphine Sulfate 80mg tablets in the USA - 25 tablet Pack 25 tablet Pack $370.00

Compare

What is Watson Morphine Sulfate 80 mg

Morphine Sulfate 80mg Extended-Release Tablets are for oral use and contain morphine sulfate, an opioid agonist.

Each tablet contains the following inactive ingredients common to all strengths: cetostearyl alcohol, hydroxyethyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, talc, and titanium dioxide.

The tablet strengths describe the amount of morphine per tablet as the pentahydrated sulfate salt (morphine sulfate).

The 15 mg tablets also contain: FD&C Blue No. 2, lactose monohydrate, polysorbate 80

The 30 mg tablets also contain: D&C Red No. 7, FD&C Blue No. 1, lactose monohydrate, polysorbate 80

The 60 mg tablets also contain: D&C Red No. 30, D&C Yellow No. 10, hydroxypropyl cellulose, lactose monohydrate

The 100 mg tablets also contain: black iron oxide

The 200 mg tablets also contain: D&C Yellow No. 10, FD&C Blue No. 1, hydroxypropyl cellulose

Morphine sulfate is an odorless, white, crystalline powder with a bitter taste. It has a solubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practically insoluble in chloroform or ether. The octanol: water partition coefficient of morphine is 1.42 at physiologic pH and the pKb is 7.9 for the tertiary nitrogen (mostly ionized at pH 7.4). Its molecular weight is 758.83 and its structural formula is:

Chemical Structure

About Watson Morphine Sulfate

Morphine Sulfate Extended-Release Tablets are for oral use and contain morphine sulfate, an agonist at the mu-opioid receptor.

Each tablet contains the following inactive ingredients common to all strengths: cetostearyl alcohol, hydroxyethyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, talc, and titanium dioxide.

The tablet strengths describe the amount of morphine per tablet as the pentahydrated sulfate salt (morphine sulfate).

The 15 mg tablets also contain: lactose monohydrate, polysorbate 80

The 30 mg tablets also contain: lactose monohydrate, polysorbate 80

The 60 mg tablets also contain: hydroxypropyl cellulose, lactose monohydrate

The 100 mg tablets also contain: black iron oxide

The 200 mg tablets also contain: hydroxypropyl cellulose

Morphine sulfat is an odorless, white, crystalline powder with a bitter taste. It has a solubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practically insoluble in chloroform or ether. The octanol: water partition coefficient of morphine is 1.42 at physiologic pH and the pKb is 7.9 for the tertiary nitrogen (mostly ionized at pH 7.4).

Limitations Of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfat extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic.

Dosage and administration

Initial Dosing
Morphine  extended-release tablets should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

Initiate the dosing regimen for each patient individually, taking into account the patient’s prior analgesic treatment experience and risk factors for addiction, abuse, and misuse. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with morphine sulfate extended-release tablets.

Morphine sulfate 80mg extended-release tablets must be taken whole. Crushing, chewing, or dissolving morphine sulfate extended-release tablets will result in uncontrolled delivery of morphine and can lead to overdose or death.

Use Of Morphine Sulfate 80mg Extended-Release Tablets As The First Opioid Analgesic
Initiate treatment with morphine sulfate  tablets with 15 mg tablets orally every 8 or 12 hours.

Use Of Morphine Sulfate Extended-Release Tablets In Patients Who Are Not Opioid Tolerant
The starting dose for patients, who are not opioid-tolerant, is morphine sulfate extended-release tablets 15 mg orally every 12 hours. Patients who are opioid-tolerant are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or an equianalgesic dose of another opioid.

Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression.

Conversion From Other Oral Morphine To Morphine Sulfate Tablets
Patients receiving other oral morphine formulations may be converted to morphine sulfate extendedrelease tablets by administering one-half of the patient’s 24-hour requirement as morphine sulfate extended-release tablets on an every-12-hour schedule or by administering one-third of the patient’s daily requirement as morphine sulfate extended-release tablets on an every-8-hour schedule.

 

Side Effect of MORPHINE SULFATE 80mg (EXTENDED RELEASE)

The following serious adverse reactions are described elsewhere in the labeling:

Addiction, Abuse, and Misuse
Life-Threatening Respiratory Depression
Neonatal Opioid Withdrawal Syndrome
Interactions with Other CNS Depressants
Hypotensive Effect
Gastrointestinal Effects
Seizures

Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Morphine sulfate  tablets may increase the risk of serious adverse reactions such as those observed with other opioid analgesics, including respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, or shock

Most Frequently Observed Reactions > MORPHINE SULFATE (EXTENDED RELEASE)

In clinical trials, the most common adverse reactions with morphine sulfate  tablets were constipation, dizziness, sedation, nausea, vomiting, sweating, dysphoria, and euphoric mood.

Some of these effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain.

Less Frequently Observed Reactions

Cardiovascular disorders: tachycardia, bradycardia, palpitations

Eye disorders: visual impairment, vision blurred, diplopia, miosis

Gastrointestinal disorders: dry mouth, diarrhea, abdominal pain, constipation, dyspepsia

General disorders and administration site conditions: chills, feeling abnormal, edema, edema peripheral, weakness

Hepatobiliary disorders: biliary colic

Metabolism and nutrition disorders: anorexia

Musculoskeletal and connective tissue disorders: muscle rigidity, muscle twitching

Nervous system disorders: presyncope, syncope, headache, tremor, uncoordinated muscle movements, convulsion, intracranial pressure increased, taste alteration, paresthesia, nystagmus

Psychiatric disorders: agitation, mood altered, anxiety, depression, abnormal dreams, hallucination, disorientation, insomnia

Renal and urinary disorders: urinary retention, urinary hesitation, antidiuretic effects

Reproductive system and breast disorders: reduced libido and/or potency

Respiratory, thoracic and mediastinal disorders: laryngospasm

Skin and subcutaneous tissue disorders: pruritus, urticaria, rash

Vascular disorders: flushing, hypotension, hypertension

MORPHINE SULFATE (EXTENDED RELEASE)

Quantity

25 tablet Pack, 50 tablet Pack, 100 tablet Pack, 250 tablet Pack, 500 tablet Pack, 1000 tablet Pack

Reviews

There are no reviews yet.

Be the first to review “Buy Watson Morphine Sulfate 80mg tablets in the USA”

Your email address will not be published. Required fields are marked *